Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety

A major UK supplier of menopause drug HRT has been sanctioned after whistleblowers claimed patients were being put at risk, it has emerged.

A group of employees from Theramex, which supplies HRT treatments to millions of patients in the UK, wrote a letter to the pharmaceutical regulator Association of the British Pharmaceutical Industry over allegations the company was not following regulatory standards and may “jeopardise” patient safety.

The whistleblowers claimed some products featured inaccurate prescribing information and failed to highlight common side effects. They claimed they had been forced to contact the regulator after their attempts to raise issues internally were brushed off.

The company has now admitted it breached regulatory codes, amounting to “bringing discredit upon, and reducing confidence in the pharmaceutical industry”, according to an interim case report from the ABPI. It also failed to maintain high standards and provide accurate and up-to-date prescribing information, the report said.

Read full story

Source: The Independent, 21 July 2025